Medicare Now Covers Obesity Medicines
The Centers for Medicare & Medicaid Services detailed how Medicare will now cover certain obesity medications — opening access for millions of Americans. This marks a major shift toward treating obesity as a chronic medical condition requiring pharmaceutical management. The change is expected to reshape both clinical practice and insurance markets nationwide.
This policy shift reverses a long-standing exclusion. A 2003 law, part of the Medicare Prescription Drug, Improvement, and Modernization Act, specifically prohibited Medicare Part D from covering drugs for weight loss. This prohibition stemmed from safety concerns with earlier anti-obesity medications in the 1990s. The new coverage specifically includes popular GLP-1 agonist drugs such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro). Previously, these drugs were only covered by Medicare if prescribed for other conditions like type 2 diabetes or to reduce cardiovascular risk, not for weight management alone. Under the new agreement, the cost for these medications will be significantly reduced. Medicare will pay $245 for the drugs, and beneficiaries will have a copay of around $50 per month. This is a steep drop from the previous list prices which could exceed $1,000 per month. The prevalence of obesity among the Medicare population is substantial, with some data indicating that over 40% of adults aged 65-74 are obese. In 2019, about 21% of all Medicare fee-for-service beneficiaries had a diagnosis of obesity. This new coverage is expected to provide access to these medications for an estimated 3.4 million Medicare beneficiaries. For years, lawmakers have introduced the bipartisan Treat and Reduce Obesity Act (TROA) to overturn the 2003 ban, though previous versions have not passed. The recent change in Medicare's policy reflects a growing recognition of obesity as a chronic disease requiring a range of treatment options, a view officially recognized by the American Medical Association in 2013. While this expansion of coverage is a significant step, access may not be immediate for all. The full implementation of this new policy is expected to roll out in mid-2026. Furthermore, state Medicaid programs will also gain access to these medications at the newly negotiated prices.
